R. Benner

发表

Contributions to survival analysis

R. Benner, 1998 .

Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease.

M. Pfeffer, C. O'connor, M. Fisher, 2006, American heart journal.

Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer

J. Nemunaitis, R. Benner, C. Belani, 2013, Cancer biology & therapy.

Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine

J. Berlin, A. Benson, A. Tan, 2012, Investigational New Drugs.

Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC).

J. Strausz, T. Mok, S. Novello, 2010 .

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

H. Dombret, S. Chevret, C. Preudhomme, 2018, Haematologica.

Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: Phase 2 study results

E. Perez, L. Denis, P. Mainwaring, 2005 .

A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India.

R. Benner, V. Dev, N. Valecha, 2005, The Journal of infectious diseases.

Clinical Pharmacokinetics and Gastrointestinal Tolerability of a Novel Extended-Release Microsphere Formulation of Azithromycin

R. Benner, Amarnath Sharma, R. Labadie, 2007, Clinical pharmacokinetics.

Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial.

Christopher M O'Connor, C. O'connor, M. Fisher, 2003, JAMA.

A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus.

P. Cahn, R. Benner, C. Hicks, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.

Keunchil Park, S. Novello, M. Krzakowski, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer.

G. Scagliotti, J. Milanowski, F. Shepherd, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.

M. Krzakowski, J. Jassem, E. Tan, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer.

L. Paz-Ares, A. Szczesna, J. Schiller, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated with Chemotherapy with or without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

H. Dombret, R. Benner, O. Legrand, 2018, Blood.

Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia

H. Dombret, R. Benner, X. Thomas, 2021, Bone Marrow Transplantation.

A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia

M. McMullin, R. Benner, E. Vandendries, 2023, Cancer Chemotherapy and Pharmacology.

Annals of Oncology

M. Krzakowski, J. Jassem, E. Tan, 2022 .

The WIZARD Trial as a Case Study of Flexible Clinical Trial Design

Thomas D. Cook, Rebecca J. Benner, Marian R. Fisher, 2006 .

P-017: MagnetisMM-7: an open label, randomized, phase 3 study of elranatamab versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after transplant

R. Benner, M. Mateos, E. Vandendries, 2022, Clinical Lymphoma, Myeloma & Leukemia.

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC)

J. Schiller, R. Rosell, R. Benner, 2008 .

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

H. Dombret, C. Preudhomme, R. Benner, 2018, Haematologica.

Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.

Keunchil Park, S. Novello, M. Krzakowski, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.